1. COVID-19 threatens M&A already in process— Physician survey shows widespread concern about access to testing and medical supplies for COVID— Novartis cancels $1B generics sale — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Post here as people resign this week and next

Discussion in 'Acorda Therapeutics' started by anonymous, Jan 2, 2020 at 12:10 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Looks like 95% off high and a 14 year low. Perhaps serging = tanking in Mumbai.
     

  2. anonymous

    anonymous Guest

    Thats just Habib. He is paid to post so RC feels good about himself.

    There is about a small much truth in his musings as there is in a CNN newscast.
     
  3. anonymous

    anonymous Guest



    Very misleading representation as share price (y axis) is more holistically shown in a natural log (base e) scale which softens the extremities. Also please note that the ACOR price has rebounded 62.5% from the low !! Well on the rebound pathway that your historical chart barely shows in its linear scale ! The chart does however clearly show Elliott Waves 1, 2 and 3 proving agin that the rebound is underway. We are well versed (Mensa) in the mathematica of x-y graphical presentations and the ill-advised methodologies that may be used to over emphasize a negative trend.
     
  4. anonymous

    anonymous Guest

    excellent post but this may be too complex for the average rank n file to understand.
     
  5. anonymous

    anonymous Guest

    Habib, you waited a whole three hours to reply to yourself. It must be sad to try and justify your own musings.

    Congrats, you are up 62% from 1.5 but down 90% from 45. Which is the bigger delta? Spin it however you like, ACOR is in the shitter.
     
  6. anonymous

    anonymous Guest

    your 62.5% rebound equates to a less than dollar. You need to increase over 2,000% to get back to your peak. Nothing to see here just a future penny stock with some folks excited about a $0.30 move. Maybe you could ask Elliot and his waves to get out and sell some inbrija because your sales folks need all the help they can get.
     
  7. anonymous

    anonymous Guest

    Not misleading , it is your actual stock chart and represents you pitiful performance and the only Ill advised methodologies are you leaderships business plans. Next trick... take a 10% price increase and sing your praises of +10% sales performance.
     
  8. anonymous

    anonymous Guest

    Leadership does not monitor or post oncpharmaa
     
  9. anonymous

    anonymous Guest

    Leadership? What "Leadership"?
    Let's all be honest, they made mistakes misguided by inflated delusions of being the next Biogen.
    Didn't listen to wise advice from Scopia to sell to UCB when they could have exit with an offer in the 30s.
    That lollipop-sucker of AH that got RC in this mess, sold his options and left.
    They haven't given any hint of a solution
    JPM was so sad.